Home/Pipeline/Analog Insulin Aspart

Analog Insulin Aspart

Diabetes

Pre-clinicalActive

Key Facts

Indication

Diabetes

Phase

Pre-clinical

Status

Active

Company

Paras Biopharmaceuticals Finland

About Paras Biopharmaceuticals Finland

Paras Biopharmaceuticals is a private, pre-revenue Finnish biotech focused on developing biosimilars and proprietary microbial expression technologies. The company operates a three-pronged business model encompassing a microbial biologics CDMO service, biosimilar technology development partnerships, and the sale of recombinant bioprocess enzymes. With a suite of proprietary platforms like Diabrid®, NobleCleav®, and Biomultifold®, Paras aims to enable cost-effective, high-yield production of complex therapeutic proteins and peptides. It is actively seeking partners to advance its pipeline of biosimilar candidates for osteoporosis, rheumatoid arthritis, and other conditions.

View full company profile

Therapeutic Areas

Osteoporosis Rheumatoid Arthritis Diabetes Oncology Ophthalmology

Other Diabetes Drugs

Drug	Company	Phase	Status
AdOral® Insulin	Adocia	Preclinical	Platform Development
Oral Insulin	Premas Biotech	Phase 3	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
Insulin Program	Biolingus	Pre-clinical	Active
Insulin Aspart Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Glargine Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Insulin Lispro Biosimilar	Meitheal Pharmaceuticals	Preclinical	Active
Liraglutide Injection	Meitheal Pharmaceuticals	Approved	Active
Diabetes Clinical Trials	DM Clinical Research	Not Specified	Active
Diabetes Therapeutic	Housey Pharmaceutical Research Laboratories	Not specified	Active
Diabetes Research	Evidation Health	Research	Active
Injectable HDV-Rapid Acting Insulin (Open Label, MoA)	Diasome Pharmaceuticals	Phase 2	Active